Penserra Capital Management LLC Aeglea Bio Therapeutics, Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.5 - $8.42 $3,920 - $9,430	-1,120 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $30 - $39	5 Added 0.45%	1,120 $8,000
Q2 2021 Aug 12, 2021	BUY	$6.32 - $8.38 $158 - $209	25 Added 2.29%	1,115 $7,000
Q1 2021 May 13, 2021	SELL	$6.76 - $8.57 $67 - $85	-10 Reduced 0.91%	1,090 $8,000
Q4 2020 Feb 12, 2021	BUY	$7.02 - $9.83 $5,054 - $7,077	720 Added 189.47%	1,100 $8,000
Q3 2020 Nov 13, 2020	BUY	$6.51 - $9.33 $2,473 - $3,545	380 New	380 $2,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.